Press
Just published in the Journal of Dermatological Treatment a review article pointing to soluble Fas Ligand (sFasL) as a promising therapeutic target for severe dermatological and non-dermatological diseases
The paper explores how selectively blocking sFasL with our innovative monoclonal antibody PC111 could potentially transform the treatment landscape for diseases like severe drug reactions (DRESS/DIHS), autoimmune disorders (SLE, RA, Sjogren's syndrome), and even acute...
Our latest review article on PC111, a fully human anti-Fas Ligand monoclonal antibody
We are proud to share our latest review article on #PC111, a fully human anti-Fas Ligand monoclonal antibody, and its potential as a disease-modifying therapy for #pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (#SJSTEN).This work highlights how...
A proud milestone for Scinai Immunotherapeutics Ltd. and our partners at PinCell srl
A proud milestone for Scinai Immunotherapeutics Ltd. and our partners at PinCell srl. Heartfelt congratulations to Dr. Roberta Lotti of PinCell srl for receiving the “Oscar of Italian Dermatology” from SIDeMaST - Società Italiana di Dermatologia e delle Malattie...
Italian Government clearance for Planned acquisition of PinCell srl
We’re excited to announce a major milestone: the Italian government has granted regulatory clearance under the Golden Power regulation for our planned acquisition of Pincell S.r.l., a pioneering Italian biotech company. "We are pleased to have received this regulatory...
Oscar of Italian Dermatology to PinCell scientist
I’m honored to have received the "Oscar of Italian Dermatology" from the SIDeMaST - Società Italiana di Dermatologia e delle Malattie Sessualmente Trasmesse, in the category of Immunopathology and Cutaneous Allergies! The awarded paper, “Blocking soluble Fas Ligand...
Webinar: A blockbuster drug candidate for devastating rare skin diseases
PC111 for Pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Il biotech italiano sfida patologie rare e orfane
La Repubblica, 08.05.2025 - L'azienda nasce come spin-off dell'Università di Modena e Reggio Emilia e si occupa di ricerca contro il pemfigo e la sindrome di Stevens-Johnson. Download this post in PDF
Scinai signs an option agreement to acquire rare diseasecompany Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund the next stage of development Pincell’s monoclonal antibody,...
PinCell’s studies open up new indications for lead candidate
Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligand.Severe...
PinCell announces 2 successful in-vivo studies for breakthrough skin disease therapy
Proprietary transgenic mouse produces human form of FasL protein May 4, 2023 - MILAN - PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent...